Fundraising Fox
/Companies
Sign in

AltrixBio

Wilmington, US · 4 known investors

Find your way into AltrixBio

83 people in our graph can introduce you to the AltrixBio team.

Sign up to see every warm intro you have to AltrixBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AltrixBio team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.

BiotechDigital Health

Founders & leadership

AT
Ali TavakkoliCo-founder
NBNancy Briefs
Nancy BriefsExecutive Chair of the Board & FounderNancy Briefs is Executive Chair and Founder of AltrixBio, a biotech company developing an oral therapy for type 2 diabetes and metabolic conditions. She brings experience as a board member and former CEO in digital health, medical devices, and pharmaceuticals, with a track record of raising capital and achieving multiple exits across portfolio companies.
JKJeff Karp
Jeff KarpCo-founder

Board

JB
John BrooksBoard director

Investors · 4

Taihill Venturelisted by Taihill VentureCambridge

How we know: Taihill Venture's portfolio page · Not right? Tell us

Walnut Venture Associateslisted by Walnut Venture AssociatesWellesley

How we know: the VCSheet dataset · Not right? Tell us

xfactor venturesreportedDedham · $100K – $200K

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$7.8M disclosed across 2 rounds · 2019–2025

▶$1.2MraisedJun 2025 · 20 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • John BrooksDirector
  • Jeffrey KarpDirector
  • Ali TavakkoliDirector
  • Nancy BriefsExecutive Officer, Director
Offering amount
$10M
Amount sold
$1.2M
Minimum investment
$10K
Finders' fees
$250K
Proceeds to insiders
$75K
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
04, 06c, 4a5
Full filing on SEC EDGAR ↗
▶$6.6MraisedJun 2025 · 50 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Jeffrey KarpDirector
  • Nancy BriefsExecutive Officer, Director
  • Ali TavakkoliDirector
  • John BrooksDirector
Offering amount
$6.6M
Amount sold
$6.6M
Minimum investment
$10K
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
04, 06c, 4a5
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Myricx BioMyricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.
Regenx BiosciencesREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.

Companies working in the same space as AltrixBio.

In the news

AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinicprnewswire.com · Sep 2025About AltrixBio - AltrixBioaltrixbio.com · Sep 2025

Frequently asked questions

What does AltrixBio do?
AltrixBio develops AJN003, a non-systemic, once-daily oral therapy for type 2 diabetes and related metabolic conditions that transiently coats the stomach and upper intestine to shift nutrient sensing and trigger a metabolic reset similar to bariatric surgery. The drug targets glycemic control and weight loss and is positioned as a complement or alternative to incretin-based (GLP-1) treatments, with potential applications in broader cardiometabolic diseases.
Who founded AltrixBio?
AltrixBio was founded by Ali Tavakkoli, Nancy Briefs, Jeff Karp.
Who are AltrixBio's investors?
AltrixBio's investors include Service Provider Capital, Taihill Venture, Walnut Venture Associates, xfactor ventures.
How much funding has AltrixBio raised?
AltrixBio has disclosed $7.8M raised across 2 rounds.
Where is AltrixBio headquartered?
AltrixBio is headquartered in Wilmington, US.